A5016318026- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Nanoparticle-Based Drug Delivery
- Bladder and Urothelial Cancer Treatments
- Gastric Cancer Management and Outcomes
- CAR-T cell therapy research
- 3D Printing in Biomedical Research
- Colorectal Cancer Surgical Treatments
- Genetic factors in colorectal cancer
- Colorectal and Anal Carcinomas
- Renal cell carcinoma treatment
- Tuberculosis Research and Epidemiology
- Lung Cancer Treatments and Mutations
- Peptidase Inhibition and Analysis
- Urinary and Genital Oncology Studies
- Liver Disease Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer, Hypoxia, and Metabolism
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Research Studies
- Epigenetics and DNA Methylation
- Immunotherapy and Immune Responses
- Immune cells in cancer
Chinese Academy of Medical Sciences & Peking Union Medical College
2013-2025
Third Affiliated Hospital of Harbin Medical University
2025
Shanghai East Hospital
2016-2024
Peking Union Medical College Hospital
2012-2021
Nanjing Drum Tower Hospital
2020
Cancer Hospital of Chinese Academy of Medical Sciences
2020
Nanjing University
2019
Shanghai Jiao Tong University
2012-2016
Tongji University
2015
Although PIWI-interacting RNAs (piRNAs) have recently been linked to human diseases, their roles and functions in malignancies remain unclear. This study aimed investigate the significance of some piRNAs colorectal cancer (CRC). Methods: We first analyzed expression profile CRC using TCGA GEO databases. The top 20 highly expressed were selected tested our tumor non-tumor tissue samples. then examined relevance significantly differentially piRNA outcomes 218 patients receiving postoperative...
Background Tislelizumab is an investigational, humanized, IgG4 monoclonal antibody with high affinity and binding specificity for programmed cell death-1 (PD-1) that was engineered to minimize FcγR on macrophages in order abrogate antibody-dependent phagocytosis, a mechanism of T-cell clearance potential resistance anti-PD-1 therapy. Methods The purpose this phase 1/2, open-label, non-comparative study examine the safety, tolerability, antitumor activity tislelizumab adult (≥18 years)...
Abstract Background Monoclonal antibodies targeting programmed death ligand 1 (PD-L1) signaling currently approved for defective mismatch repair (dMMR)/microsatellite instability high (MSI-H) tumors must be delivered by intravenous infusion. Envafolimab, a humanized single-domain anti-PD-L1 antibody fused to an Fc fragment, represents potential advance because it can conveniently administered subcutaneously. Methods This open-label, single-arm, phase 2 study evaluated the efficacy and safety...
Abstract Purpose: This study aimed to investigate the biomarkers of sintilimab (anti–PD-1) plus IBI305 (a bevacizumab biosimilar) in advanced hepatocellular carcinoma (HCC), as well their safety and efficacy. Patients Methods: A total 50 patients with HCC received (200 mg) (7.5 or 15 mg/kg), treated every 3 weeks a phase Ib clinical study. We performed baseline serum cytokine analysis using bead-based multiplex immunoassay immunofluorescence on tissue specimens discover novel response...
A Phase II study was undertaken to evaluate the safety and efficacy of neoadjuvant socazolimab, a novel PD-L1 inhibitor, in combination with nab-paclitaxel cisplatin for locally advanced esophageal squamous cell carcinoma (ESCC).Sixty-four patients were randomly divided between Socazolimab + (TP) arm (n = 32) control 32), receiving either socazolimab (5 mg/kg intravenously (IV), day 1) or placebo (125 mg/m2 IV, 1/8) (75 repeated every 21 days four cycles before surgery. The primary endpoint...
The immune checkpoint protein programmed cell death ligand 1 (PD-L1) binds to PD1 promote tumor escape from the killing effect of system. However, there are few studies on regulatory mechanisms PD-L1 in tumors. Although has been reported undergo ubiquitination some cancers, its oral squamous carcinoma (OSCC) unclear. Therefore, we aimed investigate this phenomenon.We examined expression and function USP9X human keratinocytes (HOK) OSCC lines (HN4 HN30) as control relevant cancer cells using...
Background and Aims: We evaluated the efficacy safety of antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 in pretreated advanced biliary tract cancers (BTCs). Approach Results: In this pooled analysis two single‐center, phase Ib clinical trials (TQB2450‐Ib‐05 TQB2450‐Ib‐08 trials), 66 patients with BTCs who had progressed or declined were ineligible for first‐line chemotherapy included. With treatment achieved complete response, 12 partial response...
3037 Background: Prognosis for advanced pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancer (BTC) remains poor, with limited treatment options available. Expression of claudin18.2 (CLDN18.2) has emerged as a potential target anti-cancer treatment. Herein, we report preliminary safety efficacy results IBI343, an antibody-drug conjugate (ADC) consisting anti-CLDN18.2 monoclonal antibody conjugated to exatecan (topoisomerase I inhibitor), in patients (pts) PDAC or BTC phase 1...
Abstract The regulation of chromosomal replication is critical and the activation DnaA by ATP binding a key step in initiation. However, it remains unclear whether how process ATP-binding to regulated. Here, we show that can be acetylated its acetylation level varies with cell growth correlates DNA initiation frequencies E. coli . Specifically, conserved K178 Walker A motif reaches summit at stationary phase, which prevents from or oriC leads inhibition deacetylation catalyzed deacetylase...
It remains unclear that how tumor immune micro-environment will change following neoadjuvant chemotherapy (NACT) in locally advanced gastric cancer (LAGC). In this study, we aimed to characterize the changes tumor-infiltrating cells and checkpoint molecules NACT investigate prognostic value of these LAGC. Paired samples (pre-NACT post-NACT) 60 patients were retrospectively identified analyzed by multiplex immunohistochemistry with a panel including CD4, CD8, FOXP3, PD-1, PD-L1, TIM3....
3514 Background: Despite the fundamental role of WNT signaling in GI cancers, especially colorectal cancer (CRC), no drug targeting has been successfully developed. CGX1321, a highly-potent and selective inhibitor O-acyltransferase Porcupine, blocks ligand secretion. Preclinical studies show that CGX1321 inhibits growth tumors with RSPO fusions or inactivating RNF43 mutations. Activation associated immune-suppression resistance to immunotherapy. Methods: The first-in-human trials...
Abstract Objective To evaluate the efficacy and safety of regorafenib monotherapy or in combination with immune-checkpoint inhibitor while treating Chinese patients metastatic colorectal cancer (mCRC): a real-world study. Methods The data who received regorafenib-containing regimen as third later line treatment at ten hospitals from Aug 2017 to Jun 2020 were retrospectively analyzed, including dosing details, survival well adverse events. Survival analysis was further performed for...
The study of DESTINY-Lung01 and DESTINY-Lung02 demonstrated the favorable efficacy optimal dosage trastuzumab deruxtecan (T-DXd) in managing human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC) patients who had received previous treatment. sought to assess cost-effectiveness T-DXd both United States (US) Chinese healthcare systems. Markov models were developed evaluate overall cost, incremental ratio (ICER), quality-adjusted life years (QALYs), (LYs)...
In urological surgery, the Da Vinci Xi robotic system has many advantages, but it also limitations such as high equipment costs and need for professional training. Kangduo is a laparoscopic surgical robot developed in China, SR2000 its newly approved four-arm robot. This study compares short-term outcomes of two radical cystectomy. Data from centre-based randomised non-inferiority trial were used patients between March 2023 June 2024 enrolled according to criteria. The primary outcome was...
4584 Background: There is still urgent medical needs in the patients with locally advanced or metastatic urothelial cancer (mUC) post to failure of at least one line chemotherapy. RC48-ADC, a novel humanized anti-HER2 antibody-drug conjugate (ADC), has proved its efficacy these (RC48-C005, NCT03507166), most whom had received gemcitabine and platinum. Taking into consideration that taxane another possible active agent for mUC, this study aims further evaluate RC48-ADC HER2 overexpressing mUC...
Streptococcus agalactiae and Candida albicans often co-colonize the female genital tract, under certain conditions induce mucosal inflammation. The role of interaction between two organisms in candidal vaginitis is not known. In this study, we found that co-infection with S. significantly attenuated hyphal development C. albicans, EFG1-Hwp1 signal pathway was involved process. a mouse model vulvovaginal candidiasis (VVC), fungal burden levels pro-inflammatory cytokines, IL-1β, IL-6 TNF-α...
According to the latest data released by National Cancer Center, colorectal cancer (CRC) had third highest incidence and fifth mortality of all malignancies, with 388,000 new cases 187,000 deaths in China (1).The Chinese Society Clinical Oncology (CSCO) originally published English version 2018 guideline concerning CRC updated them 2019 (2,3).According progress, clinical guidelines have been updated.Here, we present main updates 2020 compared version.
Abstract Accurate presurgical prediction of pathological complete response (pCR) can guide treatment decisions, potentially avoiding unnecessary surgeries and improving the quality life for cancer patients. We developed a minimal residual disease (MRD) profiling approach with enhanced sensitivity specificity detecting tumor DNA from cell-free (cfDNA). The was validated in two independent esophageal squamous cell carcinoma (ESCC) cohorts. In cohort undergoing neoadjuvant, surgical, adjuvant...